US and UK researchers launch trial to study treatment approaches for multiple sclerosis
Researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, UK, have collaborated with a team from the Cleveland Clinic in Ohio, US, for a clinical trial for the treatment of multiple sclerosis (MS).
Elisabet Guillam ó, Álvaro Cobo-Calvo, Guillermo R. Oviedo, Noémie Travier, Juan Álamo, Oscar A. Niño-Mendez, Antonio Martínez-Yelamos, Sergio Martínez-Yelamos, Casimiro Javierre
AbstractCladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad®) represent the first short-course oral disease-modifying drug (DMD) for use in MS. The tablets, administered in two short courses 1 year apart, are indicated for the treatment of adults with highly active relapsing MS on the basis of data from pivotal clinical trials, including the phase 3 study CLARITY and its extension. A cumulative cladribine tablets dose of 3.5 mg/kg administered in this fashion in CLARITY reduced clini...
CONCLUSIONS: Nonconfluent lesions of>3 mm with ≥1 central vein were the most sensitive and specific differentiators between patients with MS and control subjects.
CONCLUSIONS: WM tract disruption accounts for a small percentage of atrophy in connected subcortical gray matter when controlling for overall disease burden and is not the primary driver in most cases.
AbstractRituximab, a monoclonal antibody to CD20, is an effective treatment for relapsing remitting multiple sclerosis (MS) reducing relapse rate by at least 50% over time. Although the mechanism for this clinical benefit is unclear, rituximab depletes circulating B cells, which can perform antigen presentation and stimulation of T cells. Another anti-CD20 drug, ocrelizumab, has recently been FDA approved to treat both relapsing remitting and progressive forms of MS. While long-term effects of ocrelizumab use are essentially unknown, long-term use of rituximab has been associated with the development of progressive multifo...
Drugs that help repair the nerve cell lining that ’s damaged in multiple sclerosis were found to target certain enzymes. The finding could help researchers develop new treatments for multiple sclerosis.
Publication date: Available online 13 August 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Barry A. HendinAbstractInterferon beta therapies have been effective in the treatment of relapsing forms of multiple sclerosis for over 2 decades. These therapies have varying routes and schedules of administration but broadly similar clinical and radiologic efficacy. The most commonly reported adverse effects are flu-like symptoms and injection site reactions. The most recent addition to the class is peginterferon beta-1a, which is administered subcutaneously every 2 weeks. Although clinically stable patients with m...
ConclusionAdministrative data can be used to identify individuals with incident ON and TM, and to distinguish those with monophasic syndromes from those with an incident presentation of MS.
Maria Blonda, Antonella Amoruso, Tommaso Martino, Carlo Avolio
Journal of Neuroimaging, EarlyView.